Enhanced productivity and functionality of Modified Ribosomally Produced Peptides (M-RIPPs)

核糖体产生的多肽(RIPP)被广泛认为是最有前途的化合物之一，具有治疗包括感染、癌症和炎症在内的许多疾病的潜力。制药业对它们非常感兴趣，但生产/修改它们的成本极其高昂--即使是毫克量。通过利用组合合成生物学中的尖端技术，该项目致力于实现世界第一，即生产足够数量的定制修饰Ripps文库(M-Ripps)，以便进行药物发现筛选。该项目结合了活跃在该领域的两个英国顶尖学术团体对RIPP生物合成所涉及的自然过程的基本知识，以及英国一家领先的IB公司在工业生物合成方面的应用专业知识。它将为M-Ripps的生产提供一个多功能但强大的技术平台，该平台将在项目开始约18个月后移交给一家剥离出来的公司成立。

Ribosomally Produced Peptides (RIPPs) are widely recognised as one of the most promising classes of compounds with the potential to treat many diseases including infection, cancer & inflammation. They are of great interest to the pharma industry, but are extremely costly to produce/modify - even in milligram amounts. Through the utilisation of cutting-edge techniques in combinatorial synthetic biology, this project sets out to achieve a world first; namely, to produce bespoke libraries of Modified RIPPs (M-RIPPs) in sufficient quantities to permit drug discovery screening. The project combines the fundamental knowledge of the natural processes involved in RIPP biosynthesis of the two premier UK academic groups active in the field with the applied expertise in industrial biosynthesis of a leading UK IB company. It will deliver a versatile yet robust technology platform for the production of M-RIPPs that will be transferred to a spinoff company to be formed around 18 months after project start.